NetworkNewsBreaks – Brain Scientific Inc. (BRSF)
Post# of 129
(Total Views: 217)
Posted On: 08/20/2021 6:26:24 PM
NetworkNewsBreaks – Brain Scientific Inc. (BRSF) Tapping into AI, ML Technology to Facilitate Early Diagnosis of Brain Disorders
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, commenced its three-stage development process with the first phase in 2018 that resulted in the creation of the NeuroCap(TM) and NeuroEEG(TM). “The second phase, currently ongoing, is focused on the development of essential cloud-based infrastructure that will be used to transmit data between patients and neurologists. The third and final phase, scheduled for later this year and into 2022 and 2023, will focus on the development of AI and ML processes to increase efficiency, consistency and accuracy of diagnostic analytics provided by the application,” reads a recent article. In the future, the company’s technology will leverage AI and ML technology with an extensive cloud-based database comprised of normal and abnormal brain data to help detect abnormal activity associated with brain-related diseases like epilepsy, dementia and pre-Alzheimer’s. With the market for neurodiagnostic devices expected to expand in tandem with the growth of neurological disorders globally, “Brain Scientific Inc. aims to address this target market by providing next-generation EEG devices that will leverage AI and ML technology to facilitate the early diagnosis of brain disorders.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, commenced its three-stage development process with the first phase in 2018 that resulted in the creation of the NeuroCap(TM) and NeuroEEG(TM). “The second phase, currently ongoing, is focused on the development of essential cloud-based infrastructure that will be used to transmit data between patients and neurologists. The third and final phase, scheduled for later this year and into 2022 and 2023, will focus on the development of AI and ML processes to increase efficiency, consistency and accuracy of diagnostic analytics provided by the application,” reads a recent article. In the future, the company’s technology will leverage AI and ML technology with an extensive cloud-based database comprised of normal and abnormal brain data to help detect abnormal activity associated with brain-related diseases like epilepsy, dementia and pre-Alzheimer’s. With the market for neurodiagnostic devices expected to expand in tandem with the growth of neurological disorders globally, “Brain Scientific Inc. aims to address this target market by providing next-generation EEG devices that will leverage AI and ML technology to facilitate the early diagnosis of brain disorders.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)